Clinical Trials on Medulloblastoma in Australia

Total 25 results

Donald Mabbott

Recruiting

Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour (Met Med Can)

Cognitive Impairment | Medulloblastoma, Childhood

Canada, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Untreated Childhood Medulloblastoma

United States, Canada, Australia, New Zealand, Switzerland, Netherlands
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

Medulloblastoma | Anaplastic Medulloblastoma

United States, Canada, Puerto Rico, Australia, Netherlands
Medical University of Vienna

Recruiting

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT (MEMMAT)

Medulloblastoma Recurrent | Ependymoma Recurrent | ATRT Recurrent

Austria, Sweden, France, Spain, United States, Czechia, Denmark, Norway
European Organisation for Research and Treatment...

Recruiting

Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I)

Medulloblastoma

France, Netherlands, Spain, Australia, Germany, Switzerland, Austria, Italy
St. Jude Children's Research Hospital
National Cancer Institute (NCI); Genentech, Inc.

Active, not recruiting

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

Medulloblastoma

United States, Canada, Australia, New Zealand
Novartis Pharmaceuticals

Completed

A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)

Medulloblastoma

France, Spain, Germany, Italy, Netherlands, United Kingdom, Canada, Australia, Sweden, United States, Brazil, Switzerland, Russian Federation
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma

Medulloblastoma | Nevoid Basal Cell Carcinoma Syndrome | Desmoplastic/Nodular Medulloblastoma | Medulloblastoma With Extensive Nodularity

United States, Canada, Puerto Rico, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Medulloblastoma | Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor | Anaplastic Medulloblastoma | Supratentorial Embryonal Tumor, Not Otherwise Specified

United States, Canada, Australia, Puerto Rico
St. Jude Children's Research Hospital
National Cancer Institute (NCI)

Completed

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Brain and Central Nervous System Tumors

United States, Australia
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

Medulloblastoma

United States, Canada, Saudi Arabia, Puerto Rico, Australia
Pfizer

Completed

Combination of Irinotecan and Temozolomide in Children With Brain Tumors.

Glioma | Medulloblastoma

Spain, France, Australia, Belgium, Denmark, United Kingdom, Italy, Poland
National Cancer Institute (NCI)

Completed

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Pineoblastoma | Recurrent Medulloblastoma | Refractory Medulloblastoma | Refractory Peripheral Primitive Neuroectodermal Tumor | Central Nervous System Neoplasm | Recurrent Primitive Neuroectodermal Tumor

United States, Canada, Puerto Rico, Australia, New Zealand
St. Jude Children's Research Hospital

Completed

Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Brain and Central Nervous System Tumors

United States, Australia, Canada
Children's Oncology Group
National Cancer Institute (NCI); Pediatric Oncology Group

Completed

Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma

Brain Tumors | Central Nervous System Tumors

United States, Puerto Rico, Switzerland, Australia, Canada
Novartis Pharmaceuticals

Completed

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Glioma | Astrocytoma | Medulloblastoma | Neuroblastoma | Rhabdomyosarcoma | Hepatoblastoma

France, Canada, Italy, Australia, United Kingdom, United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Ependymoma | Childhood Craniopharyngioma | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood Infratentorial Ependymoma | Childhood... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
Bristol-Myers Squibb
Nektar Therapeutics

Terminated

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer (PIVOT IO 020)

Ewing Sarcoma | Ependymoma | Medulloblastoma | Neuroblastoma | Rhabdomyosarcoma | High-grade Glioma | Leukemia and Lymphoma | Miscellaneous Brain Tumors | Miscellaneous Solid Tumors | Relapsed, Refractory Malignant Neoplasms

United States, Australia, France, Germany, Italy, Spain
Universitätsklinikum Hamburg-Eppendorf
Deutsche Kinderkrebsstiftung

Active, not recruiting

International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

Brain Tumors

Germany, Denmark, United Kingdom, Belgium, Poland, Ireland, Austria, Italy, Czechia, France, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors

Brain Tumor | Central Nervous System Tumor

United States, Canada, Puerto Rico, Australia, Netherlands, Switzerland
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico, Australia
National Cancer Institute (NCI)
Children's Oncology Group

Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Lymphoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant... and other conditions

United States, Puerto Rico, Australia
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Sarcoma | Ovarian Cancer | Brain Tumor | Ototoxicity | Neuroblastoma | Liver Cancer | Central Nervous System Tumor | Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor

Canada, United States, Australia

Clinical Trials on Medulloblastoma in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations